109 related articles for article (PubMed ID: 119815)
1. [The changes of the OEP-HA titer in the sera of mice challenged with Pseudomonas aeruginosa and in the phagocytic system of macrophages in vitro (author's transl)].
Satomi N; Haranaka K; Kunii O; Mashimo K
Kansenshogaku Zasshi; 1979 Aug; 53(8):350-8. PubMed ID: 119815
[No Abstract] [Full Text] [Related]
2. [The influence of anti-OEP-IgG and -IgM upon mouse spleen macrophage. Phagocytic activity against Pseudomonas aeruginosa and OEP-coated latex granules (author's transl)].
Haranaka K; Matsuo M; Satomi N; Kunii O; Mashimo K
Kansenshogaku Zasshi; 1978 Nov; 52(11):482-9. PubMed ID: 107248
[No Abstract] [Full Text] [Related]
3. The role of OEP-antibodies in Pseudomonas aeruginosa infection.
Doi T; Nakajima T
Jpn J Exp Med; 1978 Aug; 48(4):287-95. PubMed ID: 101701
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic effects of anti-OEP-antibodies in the Pseudomonas aeruginosa (Fisher's seven serotypes) infection of mice and the influence of this antibody upon the phagocytic activity of mice spleen macrophages (author's transl)].
Haranaka K; Satomi N; Matsuo M; Kunii O; Mashimo K
Kansenshogaku Zasshi; 1979 Apr; 53(4):175-81. PubMed ID: 89175
[No Abstract] [Full Text] [Related]
5. [Studies on the Pseudomonas aeruginosa infections--frequency, antibiotics sensitivity, OEP-HA titer (author's transl)].
Satomi N; Haranaka K; Fukaya K; Kunii O; Mashimo K
Kansenshogaku Zasshi; 1979 Apr; 53(4):167-74. PubMed ID: 112204
[No Abstract] [Full Text] [Related]
6. Common protective antigen between Pseudomanas aeruginosa and Vibrio cholerae.
Yamamoto A; Homma JY; Ghoda A; Ishihara T; Takeuchi S
Jpn J Exp Med; 1979 Dec; 49(6):383-90. PubMed ID: 120454
[TBL] [Abstract][Full Text] [Related]
7. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
Jones RJ; Roe EA
Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
[TBL] [Abstract][Full Text] [Related]
8. [Dynamics of humoral antibody formation against the O-antigen of Pseudomonas aeruginosa in suppurative diseases].
Zarubina EK; Svetukhin AM; Edvabnaia LS
Khirurgiia (Mosk); 1980 Nov; (11):47-52. PubMed ID: 6777579
[No Abstract] [Full Text] [Related]
9. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.
Moody MR; Kessel RW; Young VM; Fiset P
Infect Immun; 1978 Sep; 21(3):905-13. PubMed ID: 101467
[TBL] [Abstract][Full Text] [Related]
10. The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.
Crowe BA; Enzersberger O; Schober-Bendixen S; Mitterer A; Mundt W; Livey I; Pabst H; Kaeser R; Eibl M; Eibl J
Antibiot Chemother (1971); 1991; 44():143-56. PubMed ID: 1801633
[No Abstract] [Full Text] [Related]
11. Pseudomonas aeruginosa antibodies in human plasma.
Doi T; Yoshioka M; Nakajima T
Jpn J Exp Med; 1976 Jun; 46(3):149-54. PubMed ID: 60502
[TBL] [Abstract][Full Text] [Related]
12. [The differentiation of OEP-HA titer between gamma-globulin products for intravenous use and their effectiveness in the passive protection of mice against Pseudomonas aeruginosa infection (author's transl)].
Haranaka K; Satomi N; Matsuo M; Fukaya K; Kunii O; Mashimo K
Kansenshogaku Zasshi; 1978 Nov; 52(11):490-6. PubMed ID: 85678
[No Abstract] [Full Text] [Related]
13. [Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
Vetkova LG; Zaĭtsev LG; Khasman EL; Radkevich SA; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):14-8. PubMed ID: 3085409
[TBL] [Abstract][Full Text] [Related]
14. Common protective antigen (OEP) of Pseudomonas aeruginosa.
Abe C; Shionoya H; Hirao Y; Okada K; Homma JY
Jpn J Exp Med; 1975 Oct; 45(5):355-9. PubMed ID: 817054
[TBL] [Abstract][Full Text] [Related]
15. [Basis for the potential production of immune preparations against Pseudomonas aeruginosa from the blood of convalescent burn patients].
Povstianoĭ NE; Kolker II; Nazarchuk LV; Fedorovskaia EA; Litovchenko PP
Gematol Transfuziol; 1984 Jul; 29(7):56-8. PubMed ID: 6205938
[No Abstract] [Full Text] [Related]
16. Role of antibody in infections due to Pseudomonas aeruginosa.
Young LS
J Infect Dis; 1974 Nov; 130 Suppl(0):S111-8. PubMed ID: 4213568
[No Abstract] [Full Text] [Related]
17. The enhancement of phagocytosis and intra-cellular killing of Pseudomonas aeruginosa and its common antigen (OEP) coated latex particles by mouse spleen macrophages to which anti-OEP-IgG and gentamicin have been added.
Haranaka K; Matsuo M; Mashimo K
Jpn J Exp Med; 1977 Feb; 47(1):35-40. PubMed ID: 404451
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa infection and vaccination in the rat.
Kostiala AA
J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
[TBL] [Abstract][Full Text] [Related]
19. Modulation of macrophage function for defence of the lung against Pseudomonas aeruginosa.
Speert DP; Wong SY; Macdonald M; Sargeant R
Behring Inst Mitt; 1997 Feb; (98):274-82. PubMed ID: 9382751
[TBL] [Abstract][Full Text] [Related]
20. Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice.
Sensakovic JW; Bartell PF
Infect Immun; 1977 Nov; 18(2):304-9. PubMed ID: 411754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
